Clinical Trials Logo

Primary Membranous Nephropathy clinical trials

View clinical trials related to Primary Membranous Nephropathy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06466135 Not yet recruiting - Clinical trials for Diabetic Nephropathies

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Start date: June 17, 2024
Phase: Phase 2
Study type: Interventional

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis [FSGS], treatment-resistant minimal change disease [TR MCD], primary immunoglobulin A nephropathy [IgAN], and primary membranous nephropathy [PMN]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.

NCT ID: NCT06120673 Not yet recruiting - Clinical trials for Primary Membranous Nephropathy

REmission in Membranous Nephropathy International Trial (REMIT)

REMIT
Start date: July 31, 2024
Phase: Phase 3
Study type: Interventional

REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada, Asia, Europe, United Kingdom, and other countries. Participants will be randomised to receive either corticosteroid and cyclophosphamide or obinutuzumab. The primary outcome is a ranked, composite measure based on (a) efficacy, defined as either complete or partial remission of PMN, (b) number of adverse events, and (c) quality of life.